This Month in Business
TrueVision and Alcon team-up on “heads-up” technology, Pfizer returns rights to ranibizumab biosimilar, and more...
- TrueVision Systems has entered a partnership agreement with Alcon for their “heads-up” 3D Digital Microscope Platform, a real-time vision system that allows surgeons (and the surgical team) to view the ophthalmic surgical field on a monitor or projector screen.
- Allergan has entered into an agreement to acquire ForSight Vision5. The deal includes an upfront payment of $95 million and a launch milestone payment for ForSight Vision5’s lead development program - a bimatoprost-eluting periocular ring for extended drug delivery in patients with glaucoma.
- Pfizer has returned its rights to PFEnex’s ranibizumab biosimilar candidate, PF582, despite Phase I/II results showing the candidate exhibits comparable safety and tolerability to ranibizumab in patients with neovascular AMD who were naïve to anti-VEGF therapy.
- Presbia Ireland (a wholly owned subsidiary of Presbia PLC) have purchased the assets of Neoptics AG, including the Swiss-based company’s comprehensive patent portfolio containing intellectual property for Microlens technology.
- In a letter to the US Department of Justice, health insurer Aetna have threatened to cut their participation in Affordable Care Act (ACA) public exchanges if they are blocked from acquiring Kentucky-based health insurer Humana.
- Several companies have released their financial figures for the second quarter of 2016: compared with the same quarter in 2015, Alimera Sciences and STAAR Surgical reported increases in revenue (66 and 12 percent, respectively); Second Sight’s revenue was $1 million, down from last year’s $2.7 million; and Ocular Therapeutix reported another net loss of $11.4 million ($1.4 million more than the same quarter in 2015).
- We interviewed James V. Mazzo about his new role at CZM and his ongoing role as Executive Chairman at Neurotech Pharmaceuticals. To find out what he had to say, click here.
